Top 5 Drug Type | Count |
---|---|
Small molecule drug | 58 |
Monoclonal antibody | 12 |
Antibody drug conjugate (ADC) | 11 |
Recombinant LBP | 6 |
Enzyme | 5 |
Target |
Mechanism IL-36R inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Sep 2022 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date26 Dec 2019 |
Target |
Mechanism dabigatran inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date16 Oct 2015 |
Start Date20 Mar 2024 |
Sponsor / Collaborator |
Start Date27 Feb 2024 |
Sponsor / Collaborator |
Start Date06 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Pramipexole Dihydrochloride ( D2 receptor x D3 receptor ) | Parkinson Disease More | Approved |
Hydrochlorothiazide/Telmisartan ( AT1R x NCC ) | Essential Hypertension More | Approved |
Linagliptin/Metformin Hydrochloride ( DPP-4 x PRKAB1 ) | Diabetes Mellitus, Type 2 More | Approved |
Bovactant(Boehringer Ingelheim GmbH) | Lung Diseases More | Approved |
Empagliflozin/Linagliptin ( DPP-4 x SGLT2 ) | Diabetes Mellitus, Type 2 More | Approved |